Modelling the Double Peak Phenomenon in pharmacokinetics

Computer Methods and Programs in Biomedicine

Volumn 104, Issue 2, 2011, Pages 62-69

  Godfrey, Keith R ^a   Arundel, Philip A ^a   Dong, Zimeng ^a   Bryant, Robert ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Compartmental models; Oral administration; Parameter estimation; Pharmacokinetics

Indexed keywords

ASTRA ZENECA; COMPARTMENTAL MODEL; DATA SETS; DOUBLE PEAK; ORAL ADMINISTRATION; PARALLEL PATHWAYS;

ABSORPTION; PARAMETER ESTIMATION; PHARMACOKINETICS; PHYSIOLOGY;

PHYSIOLOGICAL MODELS;

VERALIPRIDE;

ARTICLE; COMPARTMENT MODEL; DOUBLE PEAK PHENOMENON; DRUG ABSORPTION; DRUG BLOOD LEVEL; HUMAN; INTESTINE ABSORPTION; JEJUNUM; MAXIMUM PLASMA CONCENTRATION; PHARMACOKINETICS; PLASMA; SINGLE DRUG DOSE; STOMACH EMPTYING;

ADMINISTRATION, ORAL; COMPUTER SIMULATION; PHARMACOKINETICS;

EID: 80054118452     PISSN: 01692607     EISSN: 18727565     Source Type: Journal    
DOI: 10.1016/j.cmpb.2010.03.007     Document Type: Article

References (28)

1. Zhou H.W., Shen J.Q., Lu M., Liang W.Q., Lin W., Zhao W.H. Pharmacokinetic analysis of enterohepatic circulation of piroxicam in rabbits. Zhongguo Yao Li Xue Bao 1992, 13:180-182.
2. Oberle R.L., Amidon G.L. The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine; an explanation for the double peak phenomenon. Journal of Pharmacokinetics and Biopharmaceutics 1987, 15:529-544.
3. Veng-Pedersen P., Miller R. Pharmacokinetics and bioavailability of cimetidine in humans. Journal of Pharmaceutical Sciences 1980, 69:394-398.
4. Okuyasana O., Forrest A., DiFrancesco R., Bilic S., Rosenkranz S., Para M.F., Adams E., Yarasheski K.E., Reichman R.C., Morse G.D. and the ACTG 5043 Protocol Team, Compartmental analysis of oral amprenavir with secondary peaks. Antimicrobial Agents and Chemotherapy 2007, 51:1822-1826.
5. Lainesse C., Frank D., Meucci V., Intorre L., Soldani G., Doucet M. Pharmacokinetics of clomipramine and desmethylclomipramine after single-dose intravenous and oral administration in cats. Journal of Veterinary Pharmacology and Therapeutics 2006, 29:271-278.
6. Marathe P.H., Sandefer E.P., Kollia G.E., Greene D.S., Barbhaiya R.H., Lipper R.A., Page R.C., Doll W.J., Ryo U.Y., Digenis G.A. In vivo evaluation of the absorption and gastrointestinal transit of avitriptan in fed and fasted subjects using gamma scintigraphy. Journal of Pharmacokinetics and Pharmacodynamics 1998, 26:1-20.
7. Grundy J.S., Eliot L.A., Kulmatycki K.M., Foster R.T. Grapefruit juice and orange juice effects on the bioavailability of nifedipine in the rat. Biopharmaceutics & Drug Disposition 1998, 19:175-183.
8. Sanaka M., Yamamoto T., Tsutsumi H., Abe K., Kuyama Y. Wagner-Nelson method for analysing the atypical double-peaked [13CO2] excretion curve in the [13C]-Octanoate gastric emptying breath test in humans. Clinical and Experimental Pharmacology and Physiology 2005, 32:590-594.
9. Chang R.K., Shojaei A.H. Effect of a lipoidic excipient on the absorption profile of compound UK 81252 in dogs after oral administration. Journal of Pharmacy and Pharmaceutical Sciences 2004, 7:8-12.
10. Ogiso T., Kasutani M., Tanaka H., Iwaki M., Tanino T. Pharmacokinetics of epinastine and a possible mechanism for double peaks in oral plasma concentration profiles. Biological and Pharmaceutical Bulletin 2001, 24:790-794.
11. Mummaneni V., Amidon G.L., Dressman J.B. Gastric pH influences the appearance of double peaks in the plasma concentration-time profiles after oral administration in dogs. Pharmaceutical Research 1995, 12:780-786.
12. Takamatsu N., Welage L.S., Hayashi Y., Yamamoto R., Barnett J.L., Shah V.P., Lesko L.J., Ramachandran C., Amidon G.L. Variability in cimetidine absorption and plasma double peaks following oral administration in the fasted state in humans: correlation with antral gastric motility. European Journal of Pharmaceutics and Biopharmaceutics 2002, 53:37-47.
13. Belle D.J., Callaghan J.T., Gorski J.C., Maya J.F., Mousa O., Wrighton S.A., Hall S.D. The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity. British Journal of Clinical Pharmacology 2002, 53:67-74.
14. Metsugi Y., Miyaji Y., Ogawara K.-I., Higaki K., Kimura T. Appearance of double peaks in plasma concentration-time profile after oral administration depends on gastric emptying profile and weight function. Pharmaceutical Research 2008, 25:886-895.
15. Plusquellec Y., Campistron G., Staveris S., Barre J., Jung L., Tillement J.P., Houin G. A double-peak phenomenon in the pharmacokinetics of veralipride after oral administration: a double-site model for drug absorption. Journal of Pharmacokinetics and Biopharmaceutics 1987, 15:225-239.
16. Regårdh C.-G., Lundborg P., Gabrielson M., Heggelund A., Kylberg-Hanssen K. Pharmacokinetics of a single intravenous and oral dose of pafenolol - a beta1-adrenoceptor antagonist with atypical absorption and disposition properties - in man. Pharmaceutical Research 1990, 7:1222-1227.
17. Lennernäs H., Regårdh C.-G. Evidence for an interaction between the β-blocker pafenolol and bile salts in the intestinal lumen of the rat leading to dose-dependent oral absorption and double peaks in the plasma concentration-time profile. Pharmaceutical Research 1993, 10:879-883.
18. Suttle A.B., Brouwer K.L. Bile flow but not enterohepatic recirculation influences the pharmacokinetics of ranitidine in the rat. Drug Metabolism and Disposition 1994, 22:224-232.
19. Yin O.Q., Tomlinson B., Chow A.H., Chow M.S. A modified two-portion absorption model to describe double-peak absorption profiles of ranitidine. Clinical Pharmacokinetics 2003, 42:179-192.
20. Piquette-Miller M., Jamali F. Pharmacokinetics and multiple peaking of acebutolol enantiomers in rats. Biopharmaceutics & Drug Disposition 1998, 18:543-556.
21. Mostafavi S.A., Foster R.T. Influence of cimetidine co-administration on the pharmacokinetics of acebutolol enantiomers and its metabolite diacetolol in a rat model: the effect of gastric pH on double-peak phenomena. International Journal of Pharmaceutics 2003, 255:81-86.
22. Piyapolrungroj N., Zhou Y.S., Li C., Liu G., Zimmermann E., Fleisher D. Cimetidine absorption and elimination in rat small intestine. Drug Metabolism and Disposition 2000, 28:65-72.
23. Wermeling D.P., Miller J.L., Archer S.M., Manaligod J.M., Rudy A.C. Bioavailability and pharmacokinetics of lorazepam after intranasal, intravenous, and intramuscular administration. Journal of Clinical Pharmacology 2001, 41:1225-1231.
24. Li J., Huynh H., Chan E. Evidence for dissolution rate-limited absorption of COL-3, a matrix metalloproteinase inhibitor, leading to the irregular absorption profile in rats after oral administration. Pharmaceutical Research 2002, 19:1655-1662.
25. Weitschies W., Bernsdorf A., Giessmann T., Zschiesche M., Modess C., Hartmann V., Mrazek C., Wegner D., Nagel S., Siegmund W. The talinolol double- peak phenomenon is likely caused by presystemic processing after uptake from gut lumen. Pharmaceutical Research 2005, 22:728-735.
26. Jacquez J.A. Compartmental Analysis in Biology and Medicine 1996, BioMedware, Ann Arbor, MI, pp. 160-162. 3rd ed.
27. Berkeley Madonna Modeling and Analysis of Dynamic Systems (April 9, 2009). http://www.berkeleymadonna.com/.
28. Mirfazaelian A., Mahmoudian M. A simple pharmacokinetics subroutine for modeling double peak phenomenon. Biopharmaceutics & Drug Disposition 2006, 27:119-124.